Brief: Pharvaris Announces Positive Top-Line Phase 2 Data From RAPIDe-1 Study Of PHVS416 For The On-Demand Treatment Of HAE Attacks
08/12/2022 13:14
Dec 8 (Reuters) - Pharvaris NV PHVS.O :
* PHARVARIS ANNOUNCES POSITIVE TOP-LINE PHASE 2 DATA FROM
RAPIDE-1
STUDY OF PHVS416 FOR THE ON-DEMAND TREATMENT OF HAE ATTACKS
* PHARVARIS NV - PRIMARY ENDPOINT MET, SUBSTANTIALLY
REDUCING HAE
ATTACK SYMPTOMS
* PHARVARIS NV - ALL SECONDARY ENDPOINTS MET
* PHARVARIS NV - PHVS416 WAS WELL TOLERATED AT ALL DOSE
LEVELS
Source text for Eikon: ID:nGNX7r8PV9
Further company coverage: PHVS.O
Recent news on Pharvaris
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Pharvaris gains after genetic disorder drug meets late-stage trial goal